Eczacıbaşı-Monrol Nuclear Products

Eczacıbaşı-Monrol, an international radiopharmaceutical supplier for nuclear medicine diagnosis and treatment, exported to 50+ countries via 7 cGMP manufacturing sites, 10 cyclotrons, and SPECT production lines. A pioneer in Lutetium-177 (theranostic therapy) production since 2019, supplying uninterruptedly to 10 countries. In March 2025, Curium Pharma completed its acquisition to expand global Lu-177 capacity.